Shares in Menlo Therapeutics had dropped nearly 50% in pre-market trading as investors shrank back on news of a Phase III failure of serlopitant.
Four months after an intercontinental merger, Menlo Therapeutics is counting yet another pair of trial failures — ones with significant consequences for the companies, their shareholders and the drug.